ArticleVirology journal2006
Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses.
Article in Virology journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 61 citations in OpenAlex.
- Nanoscale Mapping of Recombinant Viral Proteins: From Cells to Virus-Like Particles.ACS photonics · 2022Article
- Production of Oral Vaccines Based on Virus-Like Particles Pseudotyped with Protozoan-Surface Proteins.Methods in molecular biology (Clifton, N.J.) · 2022Article
- The interplays between Crimean-Congo hemorrhagic fever virus (CCHFV) M segment-encoded accessory proteins and structural proteins promote virus assembly and infectivity.PLoS pathogens · 2020Article
- Article
- Progress in the development of virus-like particle vaccines against respiratory viruses.Expert review of vaccines · 2020Review
- The amino-terminus of the hepatitis C virus (HCV) p7 viroporin and its cleavage from glycoprotein E2-p7 precursor determine specific infectivity and secretion levels of HCV particle types.PLoS pathogens · 2017Article
- Yield Optimisation of Hepatitis B Virus Core Particles in E. coli Expression System for Drug Delivery Applications.Scientific reports · 2017Article
- Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger.Nanoscale · 2017Review
- Progress in developing virus-like particle influenza vaccines.Expert review of vaccines · 2016Review
- Pseudotype-based neutralization assays for influenza: a systematic analysis.Frontiers in immunology · 2015Review
- Mammalian models for the study of H7 virus pathogenesis and transmission.Current topics in microbiology and immunology · 2014Review
- Enhanced protective efficacy of H5 subtype influenza vaccine with modification of the multibasic cleavage site of hemagglutinin in retroviral pseudotypes.Virologica Sinica · 2013Article
- Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches.Virology journal · 2013Review
- Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines.The Journal of infectious diseases · 2013Article
- Review
- Developments of subunit and VLP vaccines against influenza A virus.Virologica Sinica · 2012Review
- Relevant uses of surface proteins--display on self-organized biological structures.Microbial biotechnology · 2012Review
- Article
- Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity.PloS one · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an urgent need to develop novel approaches to vaccination against the emerging, highly pathogenic avian influenza viruses. Here, we engineered influenza viral-like particles (Flu-VLPs) derived from retroviral core particles that mimic the properties of the viral surface of two highly pathogenic influenza viruses of either H7N1 or H5N1 antigenic subtype. We demonstrate that, upon recovery of viral RNAs from a field strain, one can easily generate expression vectors that encode the HA, NA and M2 surface proteins of either virus and prepare high-titre Flu-VLPs. We characterise these Flu-VLPs incorporating the HA, NA and M2 proteins and we show that they induce high-titre neutralising antibodies in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.